Morgan Stanley Adial Pharmaceuticals, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.24 - $0.56 $10 - $23	-42 Reduced 7.28%	535 $0
Q4 2022 Feb 14, 2023	SELL	$0.2 - $9.25 $89 - $4,125	-446 Reduced 43.6%	577 $0
Q3 2022 Nov 14, 2022	BUY	$0.03 - $46.0 $14 - $22,448	488 Added 91.21%	1,023 $0
Q1 2022 May 13, 2022	SELL	$45.0 - $69.0 $135 - $207	-3 Reduced 0.56%	535 $1,000
Q4 2021 Feb 14, 2022	SELL	$62.25 - $104.5 $2.47 Million - $4.15 Million	-39,690 Reduced 98.66%	538 $1,000
Q3 2021 Nov 15, 2021	BUY	$57.75 - $116.75 $2.32 Million - $4.7 Million	40,228 New	40,228 $173,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $26M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.